These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 27134180)

  • 1. Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients.
    Jiménez-Valerio G; Martínez-Lozano M; Bassani N; Vidal A; Ochoa-de-Olza M; Suárez C; García-Del-Muro X; Carles J; Viñals F; Graupera M; Indraccolo S; Casanovas O
    Cell Rep; 2016 May; 15(6):1134-43. PubMed ID: 27134180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma.
    Su SC; Hu X; Kenney PA; Merrill MM; Babaian KN; Zhang XY; Maity T; Yang SF; Lin X; Wood CG
    Clin Cancer Res; 2013 Dec; 19(23):6461-72. PubMed ID: 24122794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.
    Hammers HJ; Verheul HM; Salumbides B; Sharma R; Rudek M; Jaspers J; Shah P; Ellis L; Shen L; Paesante S; Dykema K; Furge K; Teh BT; Netto G; Pili R
    Mol Cancer Ther; 2010 Jun; 9(6):1525-35. PubMed ID: 20501804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.
    Han KS; Raven PA; Frees S; Gust K; Fazli L; Ettinger S; Hong SJ; Kollmannsberger C; Gleave ME; So AI
    Neoplasia; 2015 Nov; 17(11):805-16. PubMed ID: 26678908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib.
    Serova M; Tijeras-Raballand A; Dos Santos C; Martinet M; Neuzillet C; Lopez A; Mitchell DC; Bryan BA; Gapihan G; Janin A; Bousquet G; Riveiro ME; Bieche I; Faivre S; Raymond E; de Gramont A
    Oncotarget; 2016 Jun; 7(25):38467-86. PubMed ID: 27509260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer.
    Rosa R; Damiano V; Nappi L; Formisano L; Massari F; Scarpa A; Martignoni G; Bianco R; Tortora G
    Br J Cancer; 2013 Aug; 109(3):686-93. PubMed ID: 23839492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.
    Zhou L; Liu XD; Sun M; Zhang X; German P; Bai S; Ding Z; Tannir N; Wood CG; Matin SF; Karam JA; Tamboli P; Sircar K; Rao P; Rankin EB; Laird DA; Hoang AG; Walker CL; Giaccia AJ; Jonasch E
    Oncogene; 2016 May; 35(21):2687-97. PubMed ID: 26364599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.
    Bridgeman VL; Wan E; Foo S; Nathan MR; Welti JC; Frentzas S; Vermeulen PB; Preece N; Springer CJ; Powles T; Nathan PD; Larkin J; Gore M; Vasudev NS; Reynolds AR
    Mol Cancer Ther; 2016 Jan; 15(1):172-83. PubMed ID: 26487278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma.
    Huang D; Ding Y; Zhou M; Rini BI; Petillo D; Qian CN; Kahnoski R; Futreal PA; Furge KA; Teh BT
    Cancer Res; 2010 Feb; 70(3):1063-71. PubMed ID: 20103651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adrenomedullin blockade suppresses sunitinib-resistant renal cell carcinoma growth by targeting the ERK/MAPK pathway.
    Gao Y; Li J; Qiao N; Meng Q; Zhang M; Wang X; Jia J; Yang S; Qu C; Li W; Wang D
    Oncotarget; 2016 Sep; 7(39):63374-63387. PubMed ID: 27556517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring the Vascular Response and Resistance to Sunitinib in Renal Cell Carcinoma
    Robinson SP; Boult JKR; Vasudev NS; Reynolds AR
    Cancer Res; 2017 Aug; 77(15):4127-4134. PubMed ID: 28566330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model.
    Diaz-Montero CM; Mao FJ; Barnard J; Parker Y; Zamanian-Daryoush M; Pink JJ; Finke JH; Rini BI; Lindner DJ
    Br J Cancer; 2016 Oct; 115(8):920-928. PubMed ID: 27560553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
    Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
    Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular disruption in combination with mTOR inhibition in renal cell carcinoma.
    Ellis L; Shah P; Hammers H; Lehet K; Sotomayor P; Azabdaftari G; Seshadri M; Pili R
    Mol Cancer Ther; 2012 Feb; 11(2):383-92. PubMed ID: 22084164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications.
    Adelaiye R; Ciamporcero E; Miles KM; Sotomayor P; Bard J; Tsompana M; Conroy D; Shen L; Ramakrishnan S; Ku SY; Orillion A; Prey J; Fetterly G; Buck M; Chintala S; Bjarnason GA; Pili R
    Mol Cancer Ther; 2015 Feb; 14(2):513-22. PubMed ID: 25519701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
    Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
    Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy using molecular-targeted drugs modulates tumor microenvironment and impairs tumor growth in renal cell carcinoma.
    Kitano H; Kitadai Y; Teishima J; Yuge R; Shinmei S; Goto K; Inoue S; Hayashi T; Sentani K; Yasui W; Matsubara A
    Cancer Med; 2017 Oct; 6(10):2308-2320. PubMed ID: 28834289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle.
    Pretto F; Ghilardi C; Moschetta M; Bassi A; Rovida A; Scarlato V; Talamini L; Fiordaliso F; Bisighini C; Damia G; Bani MR; Piccirillo R; Giavazzi R
    Oncotarget; 2015 Feb; 6(5):3043-54. PubMed ID: 25460504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical evidence that MNK/eIF4E inhibition by cercosporamide enhances the response to antiangiogenic TKI and mTOR inhibitor in renal cell carcinoma.
    Chen S; Cui L; Hu Q; Shen Y; Jiang Y; Zhao J
    Biochem Biophys Res Commun; 2020 Sep; 530(1):142-148. PubMed ID: 32828276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.